A Phase 1 Bioavailability and Food Effect Study to Compare Tablet Versus Solution Formulation and to Assess the Effect of Food on the Bioavailability of a Single TAK-935 Dose in Healthy Subjects
Latest Information Update: 16 Jan 2020
At a glance
- Drugs Soticlestat (Primary) ; Soticlestat (Primary)
- Indications Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Myoclonic epilepsies; Tuberous sclerosis
- Focus Pharmacokinetics
- Sponsors Takeda
- 15 Nov 2016 Status changed from recruiting to completed.
- 06 Oct 2016 Status changed from not yet recruiting to recruiting.
- 29 Sep 2016 New trial record